These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 11779207)

  • 1. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
    Sliva D; English D; Lyons D; Lloyd FP
    Biochem Biophys Res Commun; 2002 Jan; 290(1):552-7. PubMed ID: 11779207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
    Sliva D; Rizzo MT; English D
    J Biol Chem; 2002 Feb; 277(5):3150-7. PubMed ID: 11689575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells.
    Das R; Mahabeleshwar GH; Kundu GC
    J Biol Chem; 2003 Aug; 278(31):28593-606. PubMed ID: 12771144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin inhibits highly invasive prostate cancer cells.
    Lloyd FP; Slivova V; Valachovicova T; Sliva D
    Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
    Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
    IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
    Mahabeleshwar GH; Kundu GC
    J Biol Chem; 2003 Dec; 278(52):52598-612. PubMed ID: 14534291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.
    Cicek M; Fukuyama R; Welch DR; Sizemore N; Casey G
    Cancer Res; 2005 May; 65(9):3586-95. PubMed ID: 15867352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
    Das R; Mahabeleshwar GH; Kundu GC
    J Biol Chem; 2004 Mar; 279(12):11051-64. PubMed ID: 14704150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast cancer cells.
    Newton TR; Patel NM; Bhat-Nakshatri P; Stauss CR; Goulet RJ; Nakshatri H
    J Biol Chem; 1999 Jun; 274(26):18827-35. PubMed ID: 10373501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M; Mourah S; Dosquet C
    Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
    Chan CF; Yau TO; Jin DY; Wong CM; Fan ST; Ng IO
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4140-9. PubMed ID: 15217951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
    Cheng CY; Hsieh HL; Sun CC; Lin CC; Luo SF; Yang CM
    J Cell Physiol; 2009 Apr; 219(1):183-93. PubMed ID: 19097143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
    Dunn SE; Torres JV; Oh JS; Cykert DM; Barrett JC
    Cancer Res; 2001 Feb; 61(4):1367-74. PubMed ID: 11245436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
    Mahabeleshwar GH; Kundu GC
    J Biol Chem; 2003 Feb; 278(8):6209-21. PubMed ID: 12477728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
    Sliva D
    Curr Cancer Drug Targets; 2004 Jun; 4(4):327-36. PubMed ID: 15180498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-κb, PKC-δ, ERK1/2, and AMPKα.
    Li H; Chen C
    Integr Cancer Ther; 2018 Jun; 17(2):511-523. PubMed ID: 28627240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
    Bagheri-Yarmand R; Mazumdar A; Sahin AA; Kumar R
    Int J Cancer; 2006 Jun; 118(11):2703-10. PubMed ID: 16381000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
    Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
    Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramide-enhanced urokinase-type plasminogen activator (uPA) release is mediated by protein kinase C in cultured microglia.
    Nakajima K; Honda S; Tohyama Y; Kurihara T; Kohsaka S
    Glia; 2000 Dec; 32(3):226-33. PubMed ID: 11102964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
    Simeone AM; Nieves-Alicea R; McMurtry VC; Colella S; Krahe R; Tari AM
    Int J Oncol; 2007 Apr; 30(4):785-92. PubMed ID: 17332916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.